A dose–response framework for online monitoring of BBB opening by focused ultrasound.
DREAM-ON-FUS refined focused ultrasound to precisely control BBB opening for safe, targeted drug delivery.
It combined neuroimaging and acoustic monitoring to build personalized, dose-controlled protocols.
Passive cavitation detection and spectral analysis of the acoustic dose.
T1-weighted contrast imaging and ΔT1 mapping of BBB opening.
Histological proof-of-concept of viral-vector (gene therapy) delivery.
Developing and validating the framework in preclinical models.
Linking acoustic emissions with quantitative MRI.
Optimizing clinical protocols and PET imaging for humans.
Safer, more effective drug-delivery strategies.
Collaborating with industry pioneers such as Insightec to translate discovery into therapy.
Funded by the Ministry of Science and Innovation through the State Research Agency (AEI), within the national research plan.
PID2020-115032RA-I00 · €193,000DREAM-ON-FUS lays the groundwork for our next-generation HIFU project.
Discover D3HIFU →